KineMed and Bayer sign drug discovery agreement

Under the terms of the agreement, KineMed will identify new therapeutic utility by applying its proprietary translational medicine technologies, AquaTag and KineMarker.

Once a disease target is established for a selected drug candidate, KineMed and Bayer Healthcare will jointly determine the best development and commercialization path.

“This is in fact the third indications discovery deal we have announced in the past year, each of which gives us the option to move into more advanced product development,” said David Fineman, president and CEO of KineMed.

KineMed said it also has over two dozen early-stage partnered collaborations. Its goal over the next 12 months is to demonstrate further acceleration of these programs and to report dose-response and efficacy findings in phase I.